Free shipping on all orders over $ 500

Bozitinib (PLB-1001)

Cat. No. M10433
Bozitinib (PLB-1001) Structure
Synonym:

CBT-101; APL-101; CBI-3103

Size Price Availability Quantity
5mg USD 330  USD330 In stock
10mg USD 495  USD495 In stock
25mg USD 890  USD890 In stock
50mg USD 1450  USD1450 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Bozitinib (PLB-1001; CBT-101) is a highly selective, blood-brain barrier permeable c-MET kinase inhibitor. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 424.38
Formula C20H15F3N8
CAS Number 1440964-89-5
Purity >99%
Solubility DMSO 50 mg/mL
Storage at -20°C
References

[1] Huimin Hu, et al. Cell. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor

Related c-Met Products
Glumetinib

Glumetinib, also known as SCC244, is a novel, potent and highly selective inhibitor of c-Met with an IC50 of 0.42 nM.

NPS-1034

NPS-1034 is a dual inhibitor of Axl and MET with IC50 values of 10.3 and 48 nM, respectively.

CEP-40783

CEP-40783 (RXDX-106) is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

Savolitinib (Volitinib)

Savolitinib (volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.

AMG 337

AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the MET receptor.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Bozitinib (PLB-1001), CBT-101; APL-101; CBI-3103 supplier, c-Met, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.